Arvinas, Inc.

NASDAQ:ARVN

17.22 (USD) • At close January 14, 2025
Bedrijfsnaam Arvinas, Inc.
Symbool ARVN
Munteenheid USD
Prijs 17.22
Beurswaarde 1,183,239,582
Dividendpercentage 0%
52-weken bereik 17.09 - 53.08
Industrie Biotechnology
Sector Healthcare
CEO Dr. John G. Houston Ph.D.
Website https://www.arvinas.com

An error occurred while fetching data.

Over Arvinas, Inc.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men

Vergelijkbare Aandelen

Tilray Brands, Inc. logo

Tilray Brands, Inc.

TLRY

1.18 USD

Corcept Therapeutics Incorporated logo

Corcept Therapeutics Incorporated

CORT

51.66 USD

PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc.

PTCT

41.81 USD

Beam Therapeutics Inc. logo

Beam Therapeutics Inc.

BEAM

23.3 USD

AbCellera Biologics Inc. logo

AbCellera Biologics Inc.

ABCL

2.77 USD

Fate Therapeutics, Inc. logo

Fate Therapeutics, Inc.

FATE

1.255 USD

Canopy Growth Corporation logo

Canopy Growth Corporation

CGC

2.22 USD

Amicus Therapeutics, Inc. logo

Amicus Therapeutics, Inc.

FOLD

9.21 USD

EQRx, Inc. logo

EQRx, Inc.

EQRX

2.34 USD

Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc.

IOVA

5.89 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)